companies

NunaBio

Founded 2021
Employees 5+
Primary contact
Bedson Building
Newcastle University
NE1 7RU Newcastle upon Tyne
United Kingdom
+44 (0) 330 229 2700
Links
https://nunabio.com/
Sections
A spin-out from Newcastle University, NunaBio has developed a platform that enables the synthesis of whole genes and DNA fragments of unprecedented length without the use of plasmids or primers, which are existing bottlenecks in the synthetic biology industry. Its technology has broad applications across multiple areas of life sciences, including gene therapy, T cell engineering, viral vector synthesis, hybridisation capture and targeted biomarker panels. The company is engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities, and has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects.
Founded 2021
Employees 5+
Primary contact
Bedson Building
Newcastle University
NE1 7RU Newcastle upon Tyne
United Kingdom
+44 (0) 330 229 2700
Links
https://nunabio.com/
Sections

Funding 💰

Total $2.5M
Select investors Northstar Ventures, Ascension, Pioneer Group, Innovate UK, Martlet Capital

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Growing market: Synthetic DNA has become a critical component of a wide range of emerging and established industries with global demand increasing rapidly. Current approaches are unable to keep up with the quantity, quality and complexity required for cutting-edge technologies. That's where NunaBio's kicks in.
  • Multi-patented technology: The company's patented tech produces synthetic DNA using enzymes rather than hazardous chemicals. It is described as extremely versatile and can also be applied to a wide range of adjacent markets.
  • Range of services: NunaBio's service offering includes the supply of DNA for a range of industries, contract research, advanced custom synthesis, process improvements, and rapid design iterations.
Last update: April 6, 2023